Biological Response Modifiers: Their Potential and Limitations in Cancer Therapeutics
- 1 January 1985
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 3 (1) , 71-83
- https://doi.org/10.3109/07357908509040609
Abstract
(1985). Biological Response Modifiers: Their Potential and Limitations in Cancer Therapeutics. Cancer Investigation: Vol. 3, No. 1, pp. 71-83. doi: 10.3109/07357908509040609Keywords
This publication has 29 references indexed in Scilit:
- Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon.The Journal of Experimental Medicine, 1984
- THE POTENTIAL USE OF IMMUNOTOXINS IN TRANSPLANTATION, CANCER THERAPY, AND IMMUNOREGULATIONTransplantation, 1984
- The thymosins—preclinical and clinical studies with fraction V and alpha-iCancer Treatment Reviews, 1984
- Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.Journal of Clinical Investigation, 1983
- Antitumor effect of arginine butyrate in conjunction withcorynebacterium parvum and interferonInternational Journal of Cancer, 1982
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.The Journal of Experimental Medicine, 1982
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration.The Journal of Experimental Medicine, 1982
- RESPONSE OF CUTANEOUS T CELL LYMPHOMA TO THERAPY WITH HYBRIDOMA MONOCLONAL ANTIBODYThe Lancet, 1981
- ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1969